Drug Trial Radar · NCT07751744
Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma
Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
113
Planned (sponsor's estimate)
Start
Apr 1, 2028
Primary completion
Mar 31, 2030
Study completion Mar 31, 2030
Sponsor
- Lead sponsor
- Jubilant Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, multicenter, open-label, dose-escalation and dose-expansion study evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), cerebrospinal fluid penetration, and preliminary antitumor activity of orally administered JBI-778, a selective PRMT5 inhibitor, in patients with brain metastases, leptomeningeal disease, or recurrent high-grade glioma. The study consists of a dose-escalation phase to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), followed by expansion cohorts to evaluate preliminary efficacy at the RP2D.
Conditions
- Brain Metastases From Solid Tumors
- Leptomeningeal Disease
- High Grade Glioma (HGG)
- Glioblastoma (GBM)
Interventions
JBI-778Drug
Drug: JBI-778 Oral capsule Strengths: 20 mg, 100 mg, 250 mg Starting dose: 40 mg daily Continuous once-daily administration in 21-day cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 - Incidence of Dose Limiting Toxicities (DLTs)Time frame: At the end of Cycle 1 (each cycle is 21 days)
- Phase 2 High-Grade Glioma Cohort: Objective Response Rate (ORR)Time frame: Up to 2 years
- Phase 2 Brain Metastases Cohort: Objective Response Rate (ORR)Time frame: Up to 2 years.
- Phase 2 Leptomeningeal Disease Cohort: Overall Survival (OS)Time frame: Up to 2 years.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.